Metastatic lung adenocarcinoma related alpha-Fetoprotein elevation in a patient with HBV-related cirrhosis
ACTA GASTRO-ENTEROLOGICA BELGICA, cilt.78, sa.4, ss.441-442, 2015 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Kısa Makale
- Cilt numarası: 78 Sayı: 4
- Basım Tarihi: 2015
- Dergi Adı: ACTA GASTRO-ENTEROLOGICA BELGICA
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
- Sayfa Sayıları: ss.441-442
- Ankara Yıldırım Beyazıt Üniversitesi Adresli: Evet
Özet
HCC is the most common type of primary liver tumor. The Practice Guideline, AASLD, for HCC recommended surveillance of HBV carriers at high risk of HCC with US every 6-12 months. Laboratory surveillance option is the measurement of serum alpha-fetoprotein level which has long been used for the diagnosis of HCC. But, increased serum levels of alpha-fetoprotein are also seen in acute hepatitis, cirrhosis, and malignancies include yolk sac carcinoma, neuroblastoma, hepatoblastoma, gastric and lung carcinoma. Because of elevation alpha-fetoprotein in these malignancies, liver mass with an elevated alpha-fetoprotein does not directly indicate HCC. For these reason, clinicians evaluating patient with liver mass and HBV-related cirrhosis should be vigilant for other case of alpha-fetoprotein elevation.